Group 1: Financial Performance - In the first three quarters of 2025, the company achieved a revenue of CNY 3.892 billion, representing a year-on-year growth of 19.06% [1] - The net profit attributable to shareholders was CNY 157 million, with a year-on-year increase of 45.21% [1] - The net profit excluding non-recurring gains and losses was CNY 151 million, reflecting a growth of 51.00% year-on-year [1] Group 2: Strategic Development - The company is implementing the "1234 strategy" to enhance collaboration across business segments, focusing on revenue and profit growth [1] - Future plans include a commitment to a long-term development strategy that balances scale and quality, innovation and tradition [2] - The company aims to build a technology-driven, innovation-led, and ecologically collaborative pharmaceutical health industry group [2] Group 3: Retail Network Expansion - Guosheng Pharmacy operates under the principle of "professional quality, affordable convenience," providing comprehensive health services [3] - As of June 30, 2025, the company had 2,266 directly operated stores across several provinces, including Anhui, Jiangsu, Zhejiang, and Fujian [3] - Future expansion will focus on optimizing resource allocation and filling market gaps, particularly in economically strong regions of East China [3] Group 4: Response to Industry Policies - The company maintains a high level of strategic sensitivity and adaptability to changes in pharmaceutical industry policies [4] - Specific measures include enhancing R&D innovation, optimizing product structure, and increasing operational efficiency to mitigate cost pressures [4] - The company emphasizes brand building and customer service to strengthen its competitive edge in retail and chronic disease management [4] - Active participation in policy guidance and market opportunities is a priority to secure a favorable position amid policy changes [4]

Financial Performance - In 2024, the company achieved a record revenue of 4.532 billion CNY, a year-on-year increase of 19.34% [3] - The net profit attributable to the parent company was 138 million CNY, up 20.09% from the previous year [3] - In Q1 2025, revenue reached 1.267 billion CNY, reflecting a 14.71% increase year-on-year [3] - The net profit for Q1 2025 was 61.22 million CNY, marking a 28.15% growth compared to the same period last year [3] Strategic Initiatives - The significant growth is attributed to the "dual-driven, full-chain symbiosis" strategy, focusing on optimizing business structure and enhancing innovation [3] - The company is actively expanding in the elderly health sector, providing chronic disease training and services through pharmacies [4] - Development of the "Fuman Medical" series targeting common diseases in the elderly, alongside the "Guojin" series of traditional Chinese medicine products [4] Brand Development - The company has established a comprehensive self-owned brand system with over 700 agency products covering various medical categories [5] - The "Shenhua Weikang" product line has seen substantial sales growth, indicating strong market potential [5] - The company is expanding its online retail presence through platforms like Douyin, JD, Tmall, and Pinduoduo [5] Market Expansion - The company plans to deepen its market presence in Zhejiang and Fujian, focusing on both existing advantages and new growth opportunities [6] - The "1234 strategy" aims to enhance collaboration across four major business platforms, creating a cohesive pharmaceutical health ecosystem [7] Future Outlook - The company will continue to expand its store network through new openings, acquisitions, and franchises, solidifying its leading position in Anhui [8] - Emphasis on balanced development across core business segments while enhancing brand influence and market share [8] - Ongoing commitment to digital transformation and operational efficiency to support high-quality growth [8]